OncoMatch/Clinical Trials/NCT06459180
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Is NCT06459180 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for cervical cancer.
Treatment: Sacituzumab Tirumotecan · Pemetrexed · Tisotumab Vedotin · Topotecan · Vinorelbine · Gemcitabine · Irinotecan — This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion. The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) expression level and in all participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — systemic
progressed on or after treatment with 1 prior line of systemic platinum doublet chemotherapy (with or without bevacizumab)
Must have received: anti-PD-1 therapy
must have received anti-PD-1/anti-PD-L1 therapy as part of prior cervical cancer regimens
Cannot have received: systemic anticancer therapy
Exception: 1 prior line allowed as specified in inclusion
Received prior systemic anticancer therapy
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Has adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USA Mitchell Cancer Institute-Clinical Trials ( Site 4126) · Mobile, Alabama
- Providence Alaska Medical Center ( Site 4137) · Anchorage, Alaska
- HonorHealth (HH) ( Site 8002) · Phoenix, Arizona
- Arizona Oncology Associates - HOPE ( Site 8001) · Tucson, Arizona
- Moores Cancer Center-Clinical Trials Office - Gynecological Oncology ( Site 4125) · La Jolla, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify